Company intelligence / Profile preview

Deep MedChem

Ownership: Private
Development stage: Commercial

Overview

Deep MedChem has developed the CHEESE AI-driven platform to accelerate early-phase drug discovery by enabling fast, accurate virtual screening and molecular property prediction. The company has over 1000 users worldwide, first paying customers, and collaborations with major chemical vendors. As a technology/platform company rather than a therapeutics developer, it does not have its own clinical results or pipeline assets.

Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

eMoleculesMculeOtava ChemicalsEnamineEIT Health

Beyond the preview

Go deeper on Deep MedChem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deep MedChem.

Explore the full profile